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Summary
Tissue development requires the controlled regulation
of cell-differentiation programs. In muscle, the Mef2
transcription factor binds to and activates the expres-
sion ofmany genes and has amajor positive role in the
orchestration of differentiation [1–4]. However, little is
known about how Mef2 activity is regulated in vivo
during development. Here, we characterize a gene,
Holes in muscle (Him), which our results indicate is
part of this control in Drosophila. Him expression rap-
idly declines as embryonic muscle differentiates, and
consistent with this,Him overexpression inhibitsmus-
cle differentiation. This inhibitory effect is suppressed
bymef2, implicatingHim in themef2 pathway.We then
found that Him downregulates the transcriptional
activity of Mef2 in both cell culture and in vivo. Further-
more, Him protein binds Groucho, a conserved, tran-
scriptional corepressor, through a WRPW motif and
requires this motif and groucho function to inhibit
both muscle differentiation and Mef2 activity during
development. Together, our results identify a mecha-
nism that can inhibit muscle differentiation in vivo.
We conclude that a balance of positive and negative
inputs, including Mef2, Him, and Groucho, controls
muscle differentiation duringDrosophila development
and suggest that one outcome is to hold developing
muscle cells in a state with differentiation genes
poised to be expressed.
Results and Discussion
Analysis of mef2 function during Drosophila muscle
development has shown that a major aspect of its role
is in the differentiation pathway downstream of the
genes that specify muscle [5–7]. However, Mef2 protein
expression precedes muscle differentiation [1]. It is first
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Michigan 48109.expressed in the mesoderm at gastrulation, approxi-
mately 3 hr after egg laying (AEL) [6]. This is approxi-
mately 7 hr before the activation at stage 13 (10 hr
AEL) of the expression of many known Mef2 target
genes, e.g., Mhc, Mlc1, and wupA ([4, 8]; data not
shown). This delay implies that the activity of Mef2 is re-
strained and that other regulatory proteins operate in the
control of muscle differentiation during this period.
However, little is known about these other proteins nor
about how the gene expression at stage 13 is coordi-
nated. Here, we address these unanswered questions
through an analysis of the Him gene in muscle differen-
tiation. Him was described in a computational screen
[9], and we isolated it separately in an expression screen
[10], but its function has not previously been analyzed.
We demonstrate that it is an inhibitor of Mef2 activity
and muscle differentiation, and on the basis of this phe-
notype, we call it Holes in muscle (Him).
Him has a striking, transient pattern of expression dur-
ing Drosophila embryogenesis. It is first expressed dur-
ing stage 9 broadly in the mesoderm (Figure 1A). This ex-
pression then refines, and at stage 12 it is specifically
expressed in the precursors of the somatic musculature
and of the heart (Figure 1C).Him expression then rapidly
declines in the somatic mesoderm, such that in 90 min it
has disappeared from the differentiating somatic mus-
cle (stage 13, Figure 1D). However, it persists in the adult
muscle precursors (AMPs), which are set aside in the so-
matic mesoderm and which remain undifferentiated at
this stage, and also in the developing heart. Him protein
expression closely resembles that of Him RNA (Figures
1E and 1F). The disappearance of Him coincides with
the expression of Myosin, a classic marker of muscle dif-
ferentiation. Double labeling with a Him-GFP fusion
gene (see Experimental Procedures in the Supplemental
Data available online) demonstrates that Myosin is ex-
pressed only after Him disappears from the developing
muscle (Figures 1G and 1H). The expression of Him in
the progenitors of the somatic muscle and its disappear-
ance from differentiating muscle are consistent with
a role for Him as an inhibitor of muscle differentiation.
Him Inhibits Muscle Differentiation In Vivo
To test whether Him is an inhibitor of muscle differentia-
tion, we overexpressed it in the developing mesoderm
by using the Gal4/UAS system [11]. This induced a dra-
matic reduction in the number of Myosin-expressing
cells and thereby produced large gaps or holes in the
musculature (Figures 1I and 1J). We then asked when
in muscle development Him has this effect. We found
that up to stage 13 (10 hr AEL) muscle development pro-
ceeds similarly to that of the wild-type. At this stage,
developing muscles are seen in the wild-type as small
syncytia, which express founder cell markers, e.g.,
Kruppel [12], and Mef2, surrounded by Mef2-expressing
myoblasts. When Him is overexpressed, the expression
of these markers is similar (Figures S1A–S1D). Subse-
quently, immunostaining for Mef2 reveals disrupted
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(A–H) Him expression decreases as muscle differentiates. In situ hybridization for Him RNA (A–D), immunostaining for Him protein (E and F), and
double immunostaining for a Him-GFP fusion protein (green) and Myosin heavy chain (Mhc) protein (red) (G and H) are shown. The anterior is
shown to the left, and dorsal side is shown uppermost, here and in all other figures. Stage 9 and 11 embryos showing that Him is initially
expressed widely in the mesoderm (arrow) are shown in (A) and (B), respectively. Stage 12 embryos (w8 hr 20 AEL) showing Him expression
in somatic muscle precursors (arrow) and heart precursors (arrowhead) are shown in (C), (E), and (G). Stage 13 embryos (w9 hr 50 AEL) showing
absence of Him expression in developing somatic muscle and continued expression in adult muscle precursors (arrow) and developing heart
(arrowhead) are shown in (D), (F), and (H).
(I and J) Him inhibits muscle differentiation in vivo. An immunostain for Mhc of stage 17 embryos with UAS-Him expression driven in the devel-
oping mesoderm by twi-Gal4;twi-Gal4 at 25C shows thatHim inhibits the terminal differentiated muscle phenotype. (I) shows the wild-type, and
(J) shows Him overexpression. A representative example of the phenotype is shown.
(K and L) Him knockdown embryos have abnormal muscle differentiation. An immunostain for Mhc of stage 17 embryos with UAS-Him RNAi
driven by twi-Gal4;twi-Gal4 at 25C shows that Him is required for correct muscle differentiation. (K) shows the wild-type, and (L) shows Him
knockdown. The Him knockdown muscle phenotype was assayed as described in Experimental Procedures. Approximately one-third of the
embryos had six or more muscles per hemisegment with abnormal morphology. (L) shows a representative example of this phenotype in which
most of the dorsal muscles are misshapen and are frequently thinner than the wild-type. Approximately one-third had a weaker phenotype, and
approximately one-third had no apparent phenotype.differentiation at stage 15, and there is increased cell
death at stage 16 (Figures S1E–S1H). Together, these
findings demonstrate thatHim inhibits the differentiation
phase, of muscle development, that occurs from
stage 13 onward and that produces the morphologically
distinct muscles of the functional musculature by the
end of embryogenesis. To explore this function further,
we knocked down Him by using RNAi from a splice-
activated UAS hairpin vector (see Experimental Proce-
dures and Figure S2). Although the musculature deve-
lops similarly to that of the wild-type, in the knockdown
there is impaired muscle differentiation as revealed by
disrupted muscle morphology (Figures 1K and 1L).
Him Genetically Interacts with mef2
We found that the overexpression of Him during muscle
development phenocopies the mef2113 hypomorphic al-
lele (Figures 2A–2D). Development of the musculature is
inhibited similarly, and many of the residual muscles
have a similar, abnormal morphology. This suggests
that the two genes function in a common pathway. Con-
sistent with this, Him and Mef2 are coexpressed in so-
matic muscle progenitors at stage 12, prior to the activa-
tion of muscle-differentiation markers such as Myosin
(Figures 2E–2G). To test whether Him and mef2 geneti-
cally interact, we overexpressed both genes together.
Strikingly, the inhibition of muscle differentiation caused
by Him is rescued toward the wild-type by mef2 (Fig-
ures 2H–2J). Furthermore, overexpression of Him aloneinduces lethality, and under the conditions of this exper-
iment only 18% survive. This lethality is suppressed by
mef2, and there are more than twice as many survivors.
Together, our phenotypic analysis and genetic interac-
tion findings indicate that Him functions in the Mef2
pathway that controls muscle differentiation.
Him Requires groucho to Mediate Its Function
The Him protein sequence includes a putative bipartite
nuclear localization signal (NLS) (Figure 3A). Consistent
with this, colocalization with the transcription factor
Twist in the AMP nuclei shows that Him is predominantly
nuclear (Figures 3B–3D). The Him protein also has
a WRPW motif at its C terminus (Figure 3A), as noted
previously [9]. This tetrapeptide in this position is found
in the Hairy group of transcriptional repressors and me-
diates their interaction with the corepressor Groucho
(Gro) [13, 14]. We used a pulldown assay to show that
Him can also bind Gro (Figure 3E). Moreover, this inter-
action requires the WRPW motif because Him with the
WRPW motif deleted (HimDWRPW) cannot bind Gro.
To investigate the importance of the WRPW for Him
function, we then overexpressed HimDWRPW in em-
bryos and found there was no dramatic loss of muscles,
in contrast to the effect of full-length Him (Figures 3F and
3G). Together, these results show that Him can bind Gro
through its WRPW tetrapeptide and that this motif is re-
quired to inhibit muscle differentiation.
Control of Drosophila Muscle Differentiation
1411We then investigated the significance of the Him/Gro
interaction in vivo during embryonic muscle develop-
ment by overexpressing Him in a gro mutant back-
ground. Strikingly, the loss of gro function suppresses
the inhibitory effect of Him (Figures 3H–3J), showing
that Him requires gro to inhibit muscle differentiation.
This result, together with our finding that mef2 can sup-
press the inhibitory effect of Him (Figure 2), indicates
that Drosophila muscle differentiation in vivo is con-
trolled by a balance between the activities of Him and
Gro on the one hand and Mef2 on the other (Figures
3K–3M). The effect of overexpression of Him can be
balanced by a reduction in Gro or by an increase in
Mef2 (Figures 2H–2J).
Him Downregulates Mef2 Activity
To further investigate the mechanism of action of Him,
we asked whether Him could inhibit Mef2 activity in
cell culture in a direct Mef2-dependent gene-expression
assay. When mef2 was transfected into S2 cells, it stim-
ulated the expression of a Mef2-responsive luciferase
reporter, and this effect was inhibited by cotransfection
with Him (Figure 4A). We then tested whether Him could
also inhibit Mef2 activity in the context of muscle
Figure 2. Him Genetically Interacts with mef2
(A–D) An immunostain for Mhc at stage 17
shows that overexpression of Him, from
24B-Gal43 UAS-Him at 25C (C and D), phe-
nocopies the mef2113 hypomorph (A and B).
(E–G) Him is expressed in somatic muscle
precursors with Mef2. Confocal microscopy
of developing somatic muscle in two hemi-
segments at stage 12 showing Him-GFP (E),
Mef2 (F), and merge (G) is shown.
(H–J) mef2 suppresses the muscle pheno-
type and lethality induced by Him overex-
pression from twi-Gal4;twi-Gal4 3 UAS-Him
at 18C. An immunostain for Mhc at stage
17 shows the wild-type differentiated muscle
pattern (H), the inhibited muscle develop-
ment from Him overexpression (I), and the
suppression of this phenotype by coexpres-
sion of UAS-mef2 with UAS-Him (J). Each
panel shows a representative phenotype for
each condition and the percentage of survival until adulthood. The number of wild-type muscles per three hemisegments in UAS-Him with
UAS-mef2was 61.06 19.0 (mean6SD, n = 51 embryos) and significantly higher than inUAS-Him alone, 39.16 20.3 (mean6SD, n = 50 embryos)
(p < 0.001, two-sample t test).
Figure 3. Him Requires gro to Mediate Its
Action
(A) Him predicted protein with a putative NLS
(see Experimental Procedures) and a C-
terminal WRPW motif, highlighted in blue
and red, respectively.
(B–D) Him is a predominantly nuclear protein.
Confocal microscopy of two AMPs showing
Him-GFP (B), the nuclear Twist protein (C),
and merge (D) is shown.
(E) Autoradiograph of a protein gel of a ‘‘pull-
down’’ assay showing that GST-Him (lane 2),
but not GST-HimDWRPW (lane 3) or GST
alone (lane 1), binds to the input radiolabelled
Groucho (lane 4).
(F and G) Him requires its WRPW motif to in-
hibit muscle differentiation. An immunostain
for Mhc at stage 17 shows that expression
of UAS-HimDWRPW driven in the developing
mesoderm by twi-Gal4;twi-Gal4 at 25C pro-
duces no dramatic loss of muscles (G), in
contrast to full-length UAS-Him (F).
(H–J) Him requires gro function to inhibit
muscle differentiation. gro suppresses the
muscle phenotype induced by Him overex-
pression from twist-Gal43UAS-Him at 25C.
An immunostain for Mhc at stage 17 shows
the wild-type differentiated muscle pattern
(H), the inhibited muscle development from Him overexpression (I), and the suppression of this phenotype in a groE48/groBX22 mutant back-
ground (J). Each panel shows a representative phenotype for each condition. The number of wild-type muscles per three hemisegments in
UAS-Him in a groucho background was 61.0 6 16.6 (mean 6 SD, n = 45 embryos) and significantly higher than in UAS-Him alone, 35.3 6 16.7
(mean 6 SD, n = 52 embryos) (p < 0.001, two-sample t test).
(K–M) Schematic representation of the balance between promoting and restraining influences controlling muscle differentiation illustrated by
these experiments.
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(A)Him inhibits Mef2 activity in cell culture. In transfected S2 cells, which contain significant levels of Gro [21], a Mef2-responsive miR1-luciferase
reporter is activated by Mef2. This effect is inhibited by cotransfection with Him.
(B–I)Him inhibits Mef2 activity in vivo during muscle development. Mef2 protein is visualized by an immunostain of stage 12 embryos (B, D, F, and
H). Somatic mesoderm expression (arrowhead) is indicated. Expression of a Mef2 target in the developing somatic muscle, b3-tubulin, is visu-
alized by in situ hybridization of stage 12 embryos (C, E, G, and I). Somatic mesoderm (arrowhead) and visceral mesoderm (arrow) expression are
indicated. (B) and (C) show the wild-type; (D) and (E) show that expression ofUAS-Him driven by twi-Gal4; twi-Gal4 at 25C does not affect Mef2
protein expression, but dramatically downregulates b3-tubulin expression in the somatic mesoderm. Expression of b3-tubulin is unaffected in
the visceral mesoderm, where it is not a Mef2 target [15], but where twi-Gal4; twi-Gal4 drives Him expression at this stage (data not shown).
Downregulation of b3-tubulin expression is not seen if either the Him C-terminal WRPW motif is deleted (F and G), or the experiment is in
a groE48/groBX22 mutant background (H and I).development. We analyzed the effect of Him overex-
pression on the expression of Mef2 and of b3-tubulin,
which is a direct Mef2 target gene in somatic muscle
[15]. b3-tubulin expression is strongly reduced in the so-
matic mesoderm, whereas Mef2 protein expression is
similar to that of the wild-type (Figures 4B–4E). This indi-
cates that Him can downregulate Mef2 activity in vivo
during embryonic development. We could further show
that Him with the Gro-interacting WRPW motif deleted
does not affect b3-tubulin expression (Figures 4F and
4G), nor does full-length Him in a groucho mutant back-
ground (Figures 4H and 4I).
Taken together, our combination of in vitro and in vivo
assays (Figures 3 and 4) reveals key features of Him’s
mechanism of action. They demonstrate that Him is
found in the nucleus and requires its Gro-binding
WRPW motif and gro function to inhibit both Mef2 activ-
ity and muscle differentiation during development. The
previously characterized Drosophila proteins that have
a C-terminal Gro-interacting WRPW motif are the Hairy
group of HLH domain DNA-binding transcriptional re-
pressors [14]. However, Him is novel and does not
have an HLH domain (see Experimental Procedures),
suggesting that it does not bind DNA directly. Its mech-
anism of action may have parallels with Ripply1, which
functions in vertebrate somitogenesis [16]. Ripply1
also appears not to be an HLH protein and yet contains
a functional Gro-interacting WRPW motif, although in
this case near the N-terminus of the protein. Like Rip-
ply1, Him may be part of a transcriptional-repressor
protein complex. The precise mechanism by which
Him targets Mef2 awaits analysis of this putative com-
plex and the protein partners within it.Conclusions
Despite considerable progress, much remains to be
learned about the regulation of muscle differentiation
during animal development. Although studies in cell cul-
ture indicate that this control might include negative
mechanisms [17–19], little is known about the identity
and mode of action of specific molecules that inhibit
muscle differentiation in vivo during development.
Here, we have identified and analyzed one mechanism
that involves Him and that can do this through targeting
Mef2, the key positive regulator of muscle differentia-
tion, and downregulating its transcriptional activity.
This inhibitory action of Him, coupled to its transient ex-
pression in developing muscle cells, is an explanation
for the observation that Mef2 is present significantly be-
fore overt differentiation. It also offers an explanation for
how a burst of expression of many Mef2 target genes at
a specific phase (stage 13) of the differentiation program
is coordinated. We suggest that the rapid decrease in
the expression of Him will lead to a concomitant in-
crease in the activity of Mef2 and the ability to activate
a cohort of these genes. Further studies will determine
whether this will link to a recent report that the ability
of Mef2 to bind DNA is temporally regulated [4].
Our results also indicate that the inhibition of Mef2 ac-
tivity by endogenous levels of Him is incomplete prior to
stage 13. Thus, in normal muscle development, the Mef2
target gene b3-tubulin is expressed at stage 12, even
though we find that overexpression of Him can downre-
gulate its expression then. This implies that in the wild-
type embryo, there is some Mef2 activity at stage 12,
and such activity is sufficient for b3-tubulin expression.
This is consistent with other work that indicates that
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earlier [3, 4, 10] and suggests that Him can provide one
level of control of Mef2 activity during the muscle-
differentiation program. Taken together, our results
move the molecular analysis of muscle differentiation
on from a simple model in which the key events are
expression of pivotal positive regulators, for example
Mef2. Rather they indicate that muscle differentiation
in vivo is controlled by a balance of positive and negative
regulators, including Him, Gro, and Mef2, that governs
whether muscle precursors differentiate. In this model,
one can think of Him and Gro as part of a mechanism
holding the cells in a committed, but undifferentiated,
state in which a cohort of muscle-differentiation genes
is poised to be expressed. This might be a widespread
strategy for coordinated gene expression in cell-
differentiation programs. For example, it can be com-
pared with melanocyte stem cell differentiation, where
cells are primed to rapidly express terminal differentia-
tion markers once Pax3/Groucho-mediated repression
is relieved [20].
Supplemental Data
Experimental Procedures and two figures are available at http://
www.current-biology.com/cgi/content/full/17/16/1409/DC1/.
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